Natera, Inc. (NASDAQ:NTRA) Insider Sells $106,772.40 in Stock

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 669 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the transaction, the insider now owns 114,142 shares of the company’s stock, valued at $18,217,063.20. This trade represents a 0.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Natera Stock Performance

Shares of NTRA opened at $159.64 on Friday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a market cap of $21.08 billion, a PE ratio of -90.70 and a beta of 1.63. Natera, Inc. has a 12 month low of $58.53 and a 12 month high of $175.63. The stock has a fifty day moving average price of $149.42 and a 200-day moving average price of $127.56.

Natera (NASDAQ:NTRA) last released its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same quarter in the previous year, the firm earned ($0.95) EPS. Natera’s revenue was up 63.9% compared to the same quarter last year. Equities research analysts predict that Natera, Inc. will post -1.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NTRA has been the topic of a number of research analyst reports. TD Cowen upped their target price on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Robert W. Baird lifted their target price on Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Piper Sandler increased their price target on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. Finally, Craig Hallum lifted their price objective on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $152.67.

Institutional Investors Weigh In On Natera

Hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its holdings in Natera by 205.4% in the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after buying an additional 1,883,481 shares in the last quarter. Farallon Capital Management LLC raised its holdings in Natera by 13.6% in the 2nd quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after purchasing an additional 532,874 shares during the period. AQR Capital Management LLC boosted its position in Natera by 257.6% during the second quarter. AQR Capital Management LLC now owns 651,523 shares of the medical research company’s stock worth $70,553,000 after purchasing an additional 469,327 shares in the last quarter. PointState Capital LP grew its holdings in Natera by 112.0% in the third quarter. PointState Capital LP now owns 782,538 shares of the medical research company’s stock valued at $99,343,000 after purchasing an additional 413,468 shares during the period. Finally, Marshall Wace LLP grew its holdings in Natera by 53.6% in the second quarter. Marshall Wace LLP now owns 958,383 shares of the medical research company’s stock valued at $103,783,000 after purchasing an additional 334,630 shares during the period. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.